Defining the risk of SARS-CoV-2 variants on immune protection
Marciela M. DeGrace,Elodie Ghedin,Matthew B. Frieman,Florian Krammer,Alba Grifoni,Arghavan Alisoltani,Galit Alter,Rama R. Amara,Ralph S. Baric,Dan H. Barouch,Jesse D. Bloom,Louis-Marie Bloyet,Gaston Bonenfant,Adrianus C. M. Boon,Eli A. Boritz,Debbie L. Bratt,Traci L. Bricker,Liliana Brown,William J. Buchser,Juan Manuel Carreño,Liel Cohen-Lavi,Tamarand L. Darling,Meredith E. Davis-Gardner,Bethany L. Dearlove,Han Di,Meike Dittmann,Nicole A. Doria-Rose,Daniel C. Douek,Christian Drosten,Venkata-Viswanadh Edara,Ali Ellebedy,Thomas P. Fabrizio,Guido Ferrari,Will M. Fischer,William C. Florence,Ron A. M. Fouchier,John Franks,Adolfo García-Sastre,Adam Godzik,Ana Silvia Gonzalez-Reiche,Aubree Gordon,Bart L. Haagmans,Peter J. Halfmann,David D. Ho,Michael R. Holbrook,Yaoxing Huang,Sarah L. James,Lukasz Jaroszewski,Trushar Jeevan,Robert M. Johnson,Terry C. Jones,Astha Joshi,Yoshihiro Kawaoka,Lisa Kercher,Marion P. G. Koopmans,Bette Korber,Eilay Koren,Richard A. Koup,Eric B. LeGresley,Jacob E. Lemieux,Mariel J. Liebeskind,Zhuoming Liu,Brandi Livingston,James P. Logue,Yang Luo,Adrian B. McDermott,Margaret J. McElrath,Victoria A. Meliopoulos,Vineet D. Menachery,David C. Montefiori,Barbara Mühlemann,Vincent J. Munster,Jenny E. Munt,Manoj S. Nair,Antonia Netzl,Anna M. Niewiadomska,Sijy O’Dell,Andrew Pekosz,Stanley Perlman,Marjorie C. Pontelli,Barry Rockx,Morgane Rolland,Paul W. Rothlauf,Sinai Sacharen,Richard H. Scheuermann,Stephen D. Schmidt,Michael Schotsaert,Stacey Schultz-Cherry,Robert A. Seder,Mayya Sedova,Alessandro Sette,Reed S. Shabman,Xiaoying Shen,Pei-Yong Shi,Maulik Shukla,Viviana Simon,Spencer Stumpf,Nancy J. Sullivan,Larissa B. Thackray,James Theiler,Paul G. Thomas,Sanja Trifkovic,Sina Türeli,Samuel A. Turner,Maria A. Vakaki,Harm van Bakel,Laura A. VanBlargan,Leah R. Vincent,Zachary S. Wallace,Li Wang,Maple Wang,Pengfei Wang,Wei Wang,Scott C. Weaver,Richard J. Webby,Carol D. Weiss,David E. Wentworth,Stuart M. Weston,Sean P. J. Whelan,Bradley M. Whitener,Samuel H. Wilks,Xuping Xie,Baoling Ying,Hyejin Yoon,Bin Zhou,Tomer Hertz,Derek J. Smith,Michael S. Diamond,Diane J. Post,Mehul S. Suthar
DOI: https://doi.org/10.1038/s41586-022-04690-5
IF: 64.8
2022-03-31
Nature
Abstract:The global emergence of many severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants jeopardizes the protective antiviral immunity induced following infection or vaccination. To address the public health threat caused by the increasing SARS-CoV-2 genomic diversity, the National Institute of Allergy and Infectious Diseases (NIAID) within the National Institutes of Health (NIH) established the SARS-CoV-2 Assessment of Viral Evolution (SAVE) program. This effort was designed to provide a real-time risk assessment of SARS-CoV-2 variants potentially impacting transmission, virulence, and resistance to convalescent and vaccine-induced immunity. The SAVE program serves as a critical data-generating component of the United States Government SARS-CoV-2 Interagency Group to assess implications of SARS-CoV-2 variants on diagnostics, vaccines, and therapeutics and for communicating public health risk. Here we describe the coordinated approach used to identify and curate data about emerging variants, their impact on immunity, and effects on vaccine protection using animal models. We report the development of reagents, methodologies, models, and pivotal findings facilitated by this collaborative approach and identify future challenges. This program serves as a template for the response against rapidly evolving pandemic pathogens by monitoring viral evolution in the human population to identify variants that could erode the effectiveness of countermeasures.
multidisciplinary sciences